Competition

Competitors describe Zoetis Inc.'s market in their own filings and calls. These verified passages and visual pages show where their strategies meet, using source documents preserved in Sources.

Elanco Animal Health Incorporated (ELAN)

Elanco is Zoetis's most direct rival — the other large, listed pure-play animal-health company (spun out of Eli Lilly). It competes head-to-head across Zoetis's biggest companion-animal franchises (parasiticides, dermatology, pain) and across livestock, names Zoetis first among its 'primary competitors,' and its recent earnings calls quantify the specific product battles — Zenrelia against Apoquel/Cytopoint in dermatology and Credelio Quattro against Simparica Trio in parasiticides.

Elanco's FY2025 10-K lists Zoetis Inc. first among its “primary competitors” in animal-health medicines and vaccines — the two large pure-play animal-health companies naming each other as the lead rival across regions, species and product categories.

We face intense competition globally. Competition may vary depending on the particular region, species, product category or individual product. We compete principally on the basis of product quality, price, cost-effectiveness, promotional effectiveness, new product development and product differentiation. […] Our primary competitors include animal health medicines and vaccines companies such as Zoetis Inc., Boehringer Ingelheim Animal Health GmbH, the animal health division of Boehringer Ingelheim GmbH, and Merck Animal Health, the animal health division of Merck & Co., Inc. We also compete with numerous other producers of animal health products throughout the world, including start-up companies working in the animal health area.

p. 17 · Read in context →

Elanco management's account of its dermatology drug Zenrelia, which it calls the “leading dermatology market share taker” in a market it sizes at $2.1 billion, now stocked in over 16,000 U.S. clinics (>50% of the total). This is the category Zoetis leads with Apoquel and Cytopoint; the framing and figures are Elanco's own (Q1 FY2026 call).

Zenrelia reached blockbuster status on a trailing four-quarter basis with a growth trajectory well exceeding our expectations even since the late February earnings call. […] We see potential for Zenrelia to be a blockbuster in both the U.S. and international as we grow the $2.1 billion global dermatology market and continue to take share. As we enter the derm season, we see Zenrelia as the leading dermatology market share taker with demonstrated strong efficacy in the JAK1 category. […] We're now at over 16,000 U.S. vet clinics or over 50% of the total, and the reorder rate is over 80%.

p. 2 · Read in context →

Elanco's stated share gains for Credelio Quattro in what it sizes as a $1.5 billion U.S. broad-spectrum parasiticide market — 53% share within stocking clinics — describe an offensive aimed at the category where Zoetis's Simparica Trio is the incumbent leader. Claims are Elanco's, from its Q1 FY2026 call.

Quattro's market share is up 3 points since Q4 and exceeding our expectations. Most importantly, in the clinics that carry Quattro, which is now over 40% of the U.S. clinic base today, our share increased 13 points in Q1, reaching 53%. […] there remains ample room for Quattro to continue to grow and take share in the $1.5 billion U.S. broad-spectrum parasiticide market. […] Outside the U.S., Quattro has made its debut in the $750 million international market, which is growing double digits.

p. 3 · Read in context →

Merck & Co., Inc. (Merck Animal Health) (MRK)

Merck & Co. is a pharmaceutical conglomerate, but its Merck Animal Health division (MSD Animal Health outside the US) is one of the two or three largest animal-health businesses globally and a direct Zoetis rival in companion-animal parasiticides and vaccines, in livestock, and in animal identification/monitoring. Only the Animal Health portions of Merck's filings and calls are used here.

Merck Animal Health's FY2025 results: the same page's segment table shows $6.35 billion of sales (livestock ~$3.9bn, companion animal ~$2.5bn); the text quoted here reports livestock up 13% and companion animal up 2%, with the Bravecto parasiticide line at ~$1.1 billion. A scale benchmark for Zoetis's own livestock and companion-animal lines.

Sales of livestock products grew 13% in 2025 primarily due to increased demand across all species, the inclusion of sales from the July 2024 acquisition of the aqua business of Elanco Animal Health Incorporated (Elanco aqua business), improved supply, new product launches, and higher pricing. […] Sales of companion animal products grew 2% in 2025 reflecting higher pricing, new product launches, and improved supply, partially offset by lower demand for other products in the portfolio. Sales of the Bravecto line of products were $1.1 billion in 2025, an increase of 1% compared with 2024.

p. 89 · Read in context →

On its Q3 2025 call, Merck attributes a 3% decline in companion-animal sales partly to “competition in parasiticides” — the category where Merck's Bravecto and Zoetis's Simparica compete directly — alongside fewer vet visits.

Our Animal Health business again delivered strong growth, with sales increasing 7%. Livestock sales grew 14%, driven by higher demand across all species as well as a benefit from timing of sales. Companion animal sales declined 3% due to a reduction in vet visits and competition in parasiticides, partially offset by price, improved supply, and new product launches.

p. 3 · Read in context →

Merck Animal Health's own product line-up — long-acting Bravecto parasiticides, the Numelvi JAK-inhibitor for allergic dermatitis, and Nobivac vaccines — maps category-for-category onto Zoetis franchises such as Simparica, Apoquel/Cytopoint and its vaccine lines.

Bravecto, a line of oral, topical and injectable parasitic control products, including the original Bravecto (fluralaner) products for dogs and cats that last up to 12 weeks; […] Numelvi (atinvicitinib), a once daily second-generation Janus kinase inhibitor for the treatment of pruritus associated with allergic dermatitis; […] Nobivac vaccine lines for flexible dog and cat vaccination, including Nobivac NXT for canine flu and feline leukemia virus

p. 9 · Read in context →

IDEXX Laboratories, Inc. (IDXX)

IDEXX is the clear leader in companion-animal veterinary diagnostics — point-of-care analyzers and reference labs — the segment Zoetis has built out (partly through its Abaxis acquisition) and is trying to grow. IDEXX's 10-K names “Zoetis Inc. (including its wholly-owned subsidiary Abaxis, Inc.)” as a direct competitor, and its calls quantify the installed-base scale and switching costs a Zoetis challenger faces.

IDEXX's FY2025 10-K names “Zoetis Inc. (including its wholly-owned subsidiary Abaxis, Inc.)” among its direct competitors in both point-of-care and reference-lab diagnostics, in North America and internationally — placing Zoetis's diagnostics segment squarely in IDEXX's competitive set.

We compete with a number of companies in most geographic locations in North America including Mars, Incorporated brands Antech Diagnostics and Heska; and Zoetis Inc. (including its wholly-owned subsidiary Abaxis, Inc.). We also compete in certain international geographies with Zoetis Inc.; Mars, Incorporated brands including Heska, Antech Diagnostics, scil animal care, and Antech-Asia Veterinary Diagnostics; Fujifilm Holdings Corporation; Arkray, Inc.; Mindray; and BioNote, Inc.

p. 19 · Read in context →

IDEXX's framing of its market (Q3 2025 call): it calls diagnostics “the fastest-growing revenue stream within veterinary clinics” and claims “global leadership in veterinary cancer diagnostics” — the growth pool and leadership position Zoetis's diagnostics segment is competing for. “Leadership” is IDEXX's own characterization.

Diagnostics remains the fastest-growing revenue stream within veterinary clinics, a durable trend reflecting the central role testing plays in determining patient health status and guiding treatment decisions. […] We also plan to bring Cancer Dx panel to international markets starting in Q1 2026, extending its reach and accelerating our global leadership in veterinary cancer diagnostics.

p. 3 · Read in context →

Phibro Animal Health Corporation (PAHC)

Phibro is a livestock-focused animal-health company that in October 2024 acquired Zoetis's medicated-feed-additive (MFA) portfolio — so its filings and calls describe, size and report on a business Zoetis divested, and it also names Zoetis among its principal competitors. Uniquely direct 'competitor talks about the subject' material on the livestock side.

Phibro's own account of the Zoetis MFA portfolio it acquired: a ~$297.5 million purchase (completed October 2024) of a business that generated $407.6 million of revenue for Zoetis in 2023, spanning 37+ product lines in ~80 countries, and which added $208.2 million to Phibro's sales in the year ended June 30, 2025 — a direct sizing of the livestock feed-additive business Zoetis exited.

In April 2024, the Company entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with Zoetis Inc., a Delaware corporation (“Zoetis”) to acquire Zoetis’s medicated feed additive (“MFA”) portfolio, certain water-soluble products and related assets (the “Acquisition”). On October 31, 2024, the Company completed the Acquisition at a purchase price of approximately $297.5 million ($286.5 million, as adjusted, net of cash acquired), subject to certain further adjustments set forth in the Purchase Agreement. […] The product portfolio acquired, which generated $407.6 million in revenue in 2023, is comprised of more than 37 product lines that are sold in approximately 80 countries. For the year ended June 30, 2025, this product portfolio contributed $208.2 million to our overall net sales.

p. 9 · Read in context →

Phibro lists Zoetis among its principal competitors in animal health and mineral nutrition — even as it now sells the MFA portfolio it bought from Zoetis — underscoring the continued livestock-segment overlap between the two.

We are engaged in highly competitive industries and, with respect to all of our major products, face competition from a substantial number of global and regional competitors. […] Some of our principal competitors include Boehringer Ingelheim International GmbH, Ceva Santé Animale, Elanco Animal Health Incorporated, Huvepharma Inc., Merck & Co., Inc. (Merck Animal Health and MSD Animal Health), Southeastern Minerals, Inc. and Zoetis. To the extent these companies or new entrants offer comparable animal health, mineral nutrition or performance products at lower prices, our business could be adversely affected.

p. 102 · Read in context →

Phibro credits the acquired “Zoetis MFA integration” with helping drive 77% growth in its MFA-and-other portfolio in Q4 FY2025 (54% for the full year) — quantifying, in the acquirer's own words, the momentum of the livestock feed-additive line Zoetis divested.

Our results this quarter reflected continued momentum across the business, led once again by Animal Health, where we saw a 53% sales growth and a 47% increase in adjusted EBITDA. Within Animal Health, our MFA and other portfolio bolstered by the Zoetis MFA integration grew 77% in the fourth quarter. […] Looking at the full year, Animal Health sales rose 36% with adjusted EBITDA up 53%. MFAs and other grew 54%, while Nutritional Specialties and Vaccines increased 9% and 13%, respectively.

p. 1 · Read in context →

Virbac (VIRP)

Virbac is an independent global pure-play animal-health company (~€1.5bn revenue) competing with Zoetis across companion-animal parasiticides, dermatology, dental and specialty nutrition, and livestock vaccines — a broad-line rival at roughly one-sixth of Zoetis's scale. Its filings are in French; key figures are rendered in the captions.

Virbac's FY2025 results as stated in its annual report: revenue of €1,465 million with +7.9% organic growth that it says ran “slightly faster than the global animal-health market,” led by companion animals (+10.9%) and North America (+14.7%). It frames itself as outgrowing the same global market Zoetis leads, with its fastest growth in the pet-health and US arenas Zoetis dominates. (Quote in French.)

Notre chifre d’afaires a atteint 1 465 millions d’euros ; à taux de change et périmètre constants, nous avons réalisé une croissance organique de 7,9%, soit une progression légèrement plus rapide que celle du marché global de la santé animale. […] Cette dynamique a été portée par une croissance de 10,9% sur notre segment des animaux de compagnie et de 6,1% sur celui des animaux d’élevage. Géographiquement, ce succès est collectif : l’Europe (+7,5%) et l’Amérique du Nord (+14,7%) ont été de puissants moteurs

p. 5 · Read in context →

Virbac's stated rationale for its 2024 Sasaeah acquisition (~€75m revenue, about half from vaccines): it claims “a leadership position in the farm animal vaccines market in Japan, notably in the cattle segment.” Livestock/cattle vaccines are a core Zoetis franchise, so this marks Virbac building regional vaccine scale in a major market where Zoetis also competes.

This strategic acquisition brings Virbac a leadership position in the farm animal vaccines market in Japan, notably in the cattle segment, and a large portfolio o pharmaceutical products for all the major species. […] Sasaeah generates annual revenues of abou €75 million, of which around 50% from vaccines.

p. 6 · Read in context →

Vetoquinol SA (VETO)

Vetoquinol is a French pure-play animal-health company (~€0.5bn revenue) that ranks itself the world's 8th-largest and competes with Zoetis in companion-animal (parasitology, dermatology, cardiology) and livestock therapeutics. Its filings offer a useful, independent sizing of the global animal-health market Zoetis leads. Filings are in French; key figures are rendered in the captions.

Vetoquinol's read of animal-health market structure: ~5% value growth in 2025 (price-driven), split roughly 55% companion / 45% livestock, with North America — chiefly the US — the single largest market at over 40% of the world and about half of the global companion-animal segment. Context for why Zoetis's US-heavy, companion-weighted revenue base sits in the richest part of the market. (Quote in French.)

En 2025, le marché mondial de la santé animale conserve une croissance positive d'environ 5 % en valeur (source : estimations Vetoquinol 2025), plus ou moins équilibrée entre le segment des animaux de compagnie (55 %) et celui des animaux d'élevage (45 %), exclusivement tirée par l'effet prix. […] L’Amérique du Nord, et plus particulièrement les États-Unis, constitue le tout premier marché de la santé animale avec plus de 40 % du marché mondial. En ce qui concerne les animaux de compagnie, le marché américain représente à lui seul environ la moitié du marché mondial de ce segment.

p. 18 · Read in context →

Competition

Elanco Animal Health Incorporated (ELAN)

Merck & Co., Inc. (Merck Animal Health) (MRK)

IDEXX Laboratories, Inc. (IDXX)

Phibro Animal Health Corporation (PAHC)

Virbac (VIRP)

Vetoquinol SA (VETO)

More peer documents